Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 23, 2005British Journal of Haematology

The course of ADAMTS‐13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMartina BöhmCBChristoph BetzGoethe University FrankfurtWMWolfgang MiesbachGoethe University Frankfurt

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Böhm et al. (2005) studied this question.

synapsesocial.com/papers/6a96e291672df19136a6dba7https://doi.org/10.1111/j.1365-2141.2005.05512.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura2004 · 453 citations
  2. 2von Willebrand factor cleaving protease (ADAMTS‐13) and ADAMTS‐13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura2004 · 159 citations
  3. 3Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome2003 · 150 citations
  4. 4Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS132003 · 90 citations